UK markets closed

BNTX Jan 2025 155.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
1.00000.0000 (0.00%)
As of 11:18AM EDT. Market open.
Full screen
Previous close1.0000
Open1.1000
Bid0.1000
Ask2.4500
Strike155.00
Expiry date2025-01-17
Day's range1.0000 - 1.1000
Contract rangeN/A
Volume50
Open interest20
  • Globe Newswire

    BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT324/DB-1311 in Prostate Cancer

    Designation is based on pre-clinical data and data from an ongoing Phase 1/2 trial for BNT324/DB-1311, with antitumor activity and a manageable safety profile demonstrated by preliminary Phase 1/2 clinical data from patients with advanced or metastatic solid tumors1,2With the Fast Track designation, the development of BNT324/DB-1311 can benefit from more frequent engagement with the U.S. Food and Drug Administration (“FDA”) to support development and expedite regulatory reviewProstate cancer is

  • Benzinga

    Covid-19 Pharma Stars Continue Their Quest To Set New Standards In Cancer Treatment

    AstraZeneca PLC (NASDAQ: AZN) kicked off the week by receiving approval from the U.S. Food and Drug Administration for its blockbuster cancer drug Imfinzi combined with chemotherapy being used as a treatment forpatients suffering from specific type of endometrial cancer. Its pharma peer, BioNTech SE (NASDAQ: BNTX) wasn’t as lucky as also on Monday, the FDA put its experimental cancer drug study on partial clinical hold. Combining Immunotherapy And Chemotherapy Is Emerging As A New Standard In Ca

  • Bloomberg

    BioNTech Cancer Drug Licensed From MediLink Faces FDA Delay

    (Bloomberg) -- The Food and Drug Administration delayed a breast- and lung-cancer trial of an experimental treatment that BioNTech SE licensed from Chinese biotech MediLink Therapeutics Ltd., citing safety concerns.Most Read from BloombergFlesh-Eating Bacteria That Can Kill in Two Days Spreads in JapanS&P 500 Hits 30th Record of 2024 as Megacaps Rally: Markets WrapThese Are the World’s Most Expensive Cities for Expats in 2024Hedge Funds’ Secret Weapon to Fight the SEC Lives in TexasHow the US Mo